

Attorney Docket No.: 4366.220-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Schulein et al.

Confirmation No: 2575

Serial No.: 10/007,521

Group Art Unit: 1652

Filed: December 5, 2001

Examiner: E. Slobodyansky

For: Endoglucanases

RECEIVED

MAY 12 2003

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT (IDS) UNDER 37 CFR 1.97(c)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which may be material to the patentability of this application and with respect to which there may be a duty to disclose. While the references may be material under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are prior art. The filing of this IDS shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.


The references are listed in Form PTO/SB/08A, which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is enclosed.

This IDS is being filed **after** the period set forth in 37 CFR 1.97(b), but **before** the mailing date of any of a final action, a notice of allowance, or an action that otherwise closes prosecution.

Accompanying this information disclosure statement is the fee set forth in 37 C.F.R. § 1.17(p). Please charge the fee, estimated to be \$180.00, to Novozymes North America, Inc., Deposit Account No. 50-1701. A duplicate of this charge directive is attached.


Respectfully submitted,

Date: May 5, 2003


Elias J. Lampiris, Reg. No. 33,728
Novozymes North America, Inc.
500 Fifth Avenue, Suite 1600
New York, NY 10110
(212)840-0097

05/09/2003 HDAHTE1 00000142 501701 10007521

01 FC:1806 180.00 CH



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/007,521		
		Filing Date	December 5, 2001		
		First Named Inventor	Schulein et al.		
		Art Unit	1652		
		Examiner Name	E. Slobodyansky		
Sheet	2	of	2	Attorney Docket Number	4366.220-US

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume- issue number(s), publisher, city and/or country where published	T ²
		Gerrit Beldman et al, Eur J. Biochem, Vol. 146, pgs. 301-308, (1985)	-
		Jones P F et al, Proc Natl Acad Sci USA, Vol. 88, pgs. 4171-4175, (1991)	-
		Damjanovski Sashko et al, Biochem J, Vol. 281, pgs. 513-517, (1992)	-
		Hayashida S. et al, Methods of Enzymology, Vol. 160, pgs. 323-332 (1992)	-
		Alfonso C. et al, FEMS Microbiol Lett, Vol. 99, pgs. 169-174, (1992)	-

RECEIVED

MAY 12 2003

TECH CENTER 1600/2900

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner of Patents, Washington, DC 20231.

PTO/SB/08A (10-01)